LYCA — Lycia Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1806540 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 156,760,000 | 60,940,000 | 288,901,000 |
| Dec 2025 | — | — | — | — | 97,215,000 | 19,268,000 | 210,554,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-136,756,000
Inventory
—
Receivables
—
ST Investments
$63,381,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,741,000 | -39,878,000 | -36,460,000 | 97,215,000 | 210,554,000 | -113,339,000 | -51,362,000 |
| Dec 2024 | 14,936,000 | -32,533,000 | -26,503,000 | 150,911,000 | 228,840,000 | -77,929,000 | -29,502,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | $439.26 | — |
| GILD | GILEAD SCIENCES, INC. | $193.48B | $156.04 | — |
| MRNA | Moderna, Inc. | $79.89B | $200.10 | — |
| ARGX | ARGENX SE | $54.33B | $873.71 | — |
| RVMD | Revolution Medicines, Inc. | $40.08B | $186.99 | — |
News headlines (Yahoo Finance, 1h cache)
Lycia Therapeutics (LYCA) Jumps After IPO With Valuation Questions Now Front And Center
2026-10-26 05:09 · Yahoo
Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere
2026-10-24 18:57 · Yahoo
Lycia Therapeutics surges in debut following upsized $317.5M IPO
2026-10-23 17:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.